Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Plasmodium berghei | glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase, putative | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | 0.0273 | 1 | 1 |
Loa Loa (eye worm) | glucose-6-phosphate dehydrogenase | 0.0263 | 0.9528 | 1 |
Toxoplasma gondii | glucose-6-phosphate 1-dehydrogenase | 0.0273 | 1 | 1 |
Trichomonas vaginalis | glucosamine-6-phosphate isomerase, putative | 0.0273 | 1 | 0.5 |
Trichomonas vaginalis | glucosamine-6-phosphate isomerase, putative | 0.0273 | 1 | 0.5 |
Onchocerca volvulus | 0.0182 | 0.5752 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.5752 | 0.6037 |
Trypanosoma cruzi | glucose-6-phosphate 1-dehydrogenase, putative | 0.0087 | 0.1264 | 0.0142 |
Trichomonas vaginalis | 6-phosphogluconolactonase, putative | 0.0273 | 1 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.395 | 0.4146 |
Leishmania major | glucose-6-phosphate 1-dehydrogenase, putative | 0.0263 | 0.9528 | 0.5 |
Schistosoma mansoni | glucose-6-phosphate 1-dehydrogenase | 0.0263 | 0.9528 | 0.5 |
Mycobacterium tuberculosis | Probable glucose-6-phosphate 1-dehydrogenase Zwf2 (G6PD) | 0.0091 | 0.1456 | 0.5 |
Echinococcus granulosus | glucose 6 phosphate 1 dehydrogenase | 0.0263 | 0.9528 | 0.5 |
Chlamydia trachomatis | glucose-6-phosphate 1-dehydrogenase | 0.0263 | 0.9528 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.395 | 0.4146 |
Treponema pallidum | glucose-6-phosphate 1-dehydrogenase | 0.0263 | 0.9528 | 0.5 |
Plasmodium vivax | glucose-6-phosphate 1-dehydrogenase, putative | 0.0273 | 1 | 0.5 |
Mycobacterium ulcerans | glucose-6-phosphate 1-dehydrogenase | 0.0263 | 0.9528 | 1 |
Brugia malayi | glucose-6-phosphate dehydrogenase | 0.0263 | 0.9528 | 1 |
Trypanosoma cruzi | glucose-6-phosphate 1-dehydrogenase, putative | 0.0263 | 0.9528 | 1 |
Brugia malayi | hypothetical protein | 0.0182 | 0.5752 | 0.6037 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.395 | 0.4146 |
Trypanosoma brucei | glucose-6-phosphate 1-dehydrogenase | 0.0263 | 0.9528 | 0.5 |
Echinococcus multilocularis | glucose 6 phosphate 1 dehydrogenase | 0.0263 | 0.9528 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 3.08 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
IC50 (functional) | = 8.01 uM | PUBCHEM_BIOASSAY: Dose Response orthogonal kinetic assay utilizing the direct detection of NADPH for uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
IC50 (functional) | > 80 uM | PUBCHEM_BIOASSAY: Human Glucose-6-Phosphate Dehydrogenase Dose Response Selectivity Assay for Inhibitors of Plasmodium falciparum Glucose-6-Phosphate Dehydrogenase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
IC50 (functional) | > 80 uM | PUBCHEM_BIOASSAY: Dose Response orthogonal assay utilizing the direct end-point detection of NADPH for uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.